J B Chemicals and Pharmaceuticals Intrinsic Value
J B Chemicals and Pharmaceuticals (JBCHEPHARM) median intrinsic value is ₹2525.00 from 10 valuation models (range ₹752–₹5977), vs current price ₹2506.00 — +0.8% upside (Trading Near Calculated Value), margin of safety 0.8%. Read JBCHEPHARM dividend yield for the complete payout history and dividend yield track record.
JBCHEPHARM Valuation Methods Summary — DCF, Graham Number & P/E
J B Chemicals and Pharmaceuticals intrinsic value across 10 models vs current price ₹2506.00 — upside/downside and value range per method. For current market price and key ratios, visit J B Chemicals and Pharmaceutic share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹751.80 | ₹601.44 - ₹902.16 | -70.0% | EPS: ₹25.40, Sector P/E: 22x |
| Book Value Method | asset | ₹5198.75 | ₹4678.88 - ₹5718.63 | +107.5% | Book Value/Share: ₹2599.38, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4580.00 | ₹4122.00 - ₹5038.00 | +82.8% | Revenue/Share: ₹2290.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4650.00 | ₹4185.00 - ₹5115.00 | +85.6% | EBITDA: ₹744.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹5976.67 | ₹4781.34 - ₹7172.00 | +138.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹751.80 | ₹676.62 - ₹826.98 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹751.80 | ₹676.62 - ₹826.98 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2525.00 | ₹2272.50 - ₹2777.50 | +0.8% | ROE: 9.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹1218.83 | ₹1096.95 - ₹1340.71 | -51.4% | EPS: ₹25.40, BVPS: ₹2599.38 |
| Dividend Yield Method | dividend | ₹880.00 | ₹792.00 - ₹968.00 | -64.9% | DPS: ₹22.00, Target Yield: 2.5% |
JBCHEPHARM Intrinsic Value vs Market Price — All Valuation Models
J B Chemicals and Pharmaceuticals fair value range ₹752–₹5977 vs current market price ₹2506.00 across 10 valuation models. Analyse J B Chemicals and Pharmaceutic shareholding analysis to track promoter, FII and institutional holdings.
JBCHEPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
J B Chemicals and Pharmaceuticals median intrinsic value ₹2525.00, current price ₹2506.00 — Trading Near Calculated Value by 0.8%, margin of safety 0.8%.
What is the intrinsic value of JBCHEPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of J B Chemicals and Pharmaceuticals (JBCHEPHARM) is ₹2525.00 (median value). With the current market price of ₹2506.00, this represents a +0.8% variance from our estimated fair value.
The valuation range spans from ₹751.80 to ₹5976.67, indicating ₹751.80 - ₹5976.67.
Is JBCHEPHARM undervalued or overvalued?
Based on our multi-method analysis, J B Chemicals and Pharmaceuticals (JBCHEPHARM) appears to be trading near calculated value by approximately 0.8%.
JBCHEPHARM Financial Health — Key Ratios vs Industry Benchmarks
J B Chemicals and Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.34 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 9.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.74x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JBCHEPHARM Cash Flow Quality — Operating & Free Cash Flow
J B Chemicals and Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹704 Cr | ₹411 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹903 Cr | ₹755 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹801 Cr | ₹599 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹626 Cr | ₹145 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹170 Cr | ₹170 Cr | Positive Free Cash Flow | 8/10 |